Abstract
Small-molecule drug discovery for cancer therapy is making extraordinary progress within the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of significant impact to both basic research and clinical testing. In this perspective, structure- and mechanism-based drug design are highlighted relative to such progress. Also, evolving concepts in novel oncogenic protein kinase inhibitor drug discovery is highlighted relative to therapeutic target selectivity, including the recent identification of oncogenic kinase mutants effecting drug-resistance or enhanced drug susceptibility to small-molecule inhibitors.
Keywords: oncogenic protein kinase, structure-based drug design, mechanism-based drug design, receptor tyrosine kinase, non-receptor tyrosine kinase, non-receptor serine/threonine kinase, atp binding site, protein kinase selectivity, sti-571, bms-354825
Current Medicinal Chemistry - Anti-Cancer Agents
Title: Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy
Volume: 4 Issue: 5
Author(s): Tomi K. Sawyer
Affiliation:
Keywords: oncogenic protein kinase, structure-based drug design, mechanism-based drug design, receptor tyrosine kinase, non-receptor tyrosine kinase, non-receptor serine/threonine kinase, atp binding site, protein kinase selectivity, sti-571, bms-354825
Abstract: Small-molecule drug discovery for cancer therapy is making extraordinary progress within the realm of advancing novel oncogenic protein kinase inhibitor lead compounds of significant impact to both basic research and clinical testing. In this perspective, structure- and mechanism-based drug design are highlighted relative to such progress. Also, evolving concepts in novel oncogenic protein kinase inhibitor drug discovery is highlighted relative to therapeutic target selectivity, including the recent identification of oncogenic kinase mutants effecting drug-resistance or enhanced drug susceptibility to small-molecule inhibitors.
Export Options
About this article
Cite this article as:
Sawyer K. Tomi, Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy, Current Medicinal Chemistry - Anti-Cancer Agents 2004; 4 (5) . https://dx.doi.org/10.2174/1568011043352830
DOI https://dx.doi.org/10.2174/1568011043352830 |
Print ISSN 1568-0118 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5968 |
Related Articles
-
The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Application of Targeted Therapy to Malignant Gliomas and Response to Treatment
Current Signal Transduction Therapy Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Distinct Roles of sAPP-α and sAPP-β in Regulating U251 Cell Differentiation
Current Alzheimer Research Co-delivery Strategies Based on Multifunctional Nanocarriers for Cancer Therapy
Current Drug Metabolism Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Applications of Lentiviral Vectors for shRNA Delivery and Transgenesis
Current Gene Therapy Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry FOXO1: A Potential Target for Human Diseases
Current Drug Targets The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
Current Molecular Medicine Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Current Drug Targets Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Aneurysm of the Communicating Vein Between the Left Renal Vein and Left Ascending Lumbar Vein Mimicking Retroperitoneal Lymphadenopathy: A Case Report
Current Medical Imaging Meet Our Editorial Board Member
Current Cancer Therapy Reviews